{"entity":{"id":"nct05255302","kind":"trial","name":"De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction","aka":["DIAL"],"tldr":"A phase 2/3 trial of pemetrexed in lung cancer, run by Intergroupe Francophone de Cancerologie Thoracique, now recruiting.","summary":"De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction is a phase 2/3, randomised interventional study registered as NCT05255302 by Intergroupe Francophone de Cancerologie Thoracique, with a registry enrolment figure of 1360 participants, started 2022-05-02 and due to reach its primary completion in 2025-05. Interventions recorded: Pembrolizumab before randomization; Chemotherapy; Pemetrexed; Pembrolizumab after randomization. Conditions listed: Metastatic NSCLC. Primary outcome: Phase II: 18-month overall survival (OS); Phase III: overall survival. Lung eligibility wording from the registry: \"Patients with histologically confirmed metastatic NSCLC (Stage IV accordingly to 8th classification TNM, UICC 2015)\". Sites: France. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT05255302","url":"https://clinicaltrials.gov/study/NCT05255302"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["pemetrexed"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05255302","phase":"2/3","setting":"A Phase II-III Randomized Trial Evaluating Maintenance Pembrolizumab (± Pemetrexed) Until Progression Versus Observation (± Pemetrexed) After 6 Months of Platinum-based Doublet Chemotherapy Plus Pembrolizumab Induction Treatment in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","enrolled":1360,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05255302/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}